Company

Knight Therapeutics Inc.

Headquarters: Montreal, QC, Canada

Founded: 1995

Employees: 679

CEO: Ms. Samira Sakhia BCom, CA, CPA, MBA

TSX: GUD +0.78%

Market Cap

C$576.8 Million

CAD as of July 1, 2024

US$420.0 Million

Market Cap History

Knight Therapeutics Inc. market capitalization over time

Evolution of Knight Therapeutics Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Knight Therapeutics Inc.

Detailed Description

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Knight Therapeutics Inc. has the following listings and related stock indices.


Stock: TSX: GUD wb_incandescent

Stock: FSX: 04K wb_incandescent

Stock: OTC: KHTRF wb_incandescent

Key People

Founder(s): Jonathan Ross Goodman

Jonathan Ross Goodman (Executive Chairman) Samira Sakhia (CEO)

Financials

Revenue: $6.16 million (2019)

Details

Headquarters:

3400 De Maisonneuve Boulevard West

Suite 1055

Montreal, QC H3Z 3B8

Canada

Phone: 514 484 4483

Fax: 514 481 4116